Trial Profile
To Demonstrate the Ability of Abatacept in Comparison to Placebo to Obtain a Low Disease Activity [PMR-AS (CRP) Lower or Equal to 10] Without GCs (Prednisone or Prednisolone) at Week 12 in Early Onset PMR Patients.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Polymyalgia rheumatica
- Focus Therapeutic Use
- Acronyms ALORS
- 01 Apr 2024 Results of an ancillary study of ALORS trial published in the European Journal of Nuclear Medicine and Molecular Imaging
- 19 May 2022 Planned End Date changed from 7 Sep 2020 to 21 Jul 2022.
- 10 May 2019 Status changed from active, no longer recruiting to recruiting.